Heroin Addiction: Treatment Options and Recovery Rates

Key Takeaways

• Heroin use disorder is a chronic medical condition with well-established, evidence-based treatment options including medication-assisted treatment (MAT) and behavioral therapies.
• Many individuals who develop heroin addiction in New Jersey initially began with prescription opioid misuse before transitioning to heroin due to cost and availability.
• MAT with buprenorphine (Suboxone/Sublocade) or methadone (Dolophine/Methadose) is the evidence-based standard of care, with significantly better outcomes than abstinence-only approaches.
• Recovery rates vary widely depending on treatment type, duration, and individual factors, but sustained treatment engagement is the single strongest predictor of positive outcomes.
• While some individuals do achieve recovery without formal treatment, research consistently shows that treated individuals have substantially better long-term outcomes.
• New Jersey offers a comprehensive treatment infrastructure including state-funded programs, Medicaid coverage for MAT, and recovery support services.

Heroin addiction remains one of the most clinically significant substance use disorders in the United States, though the landscape has shifted dramatically with the emergence of fentanyl as the dominant illicit opioid. Understanding heroin use disorder in its current context — including treatment options, what the data says about recovery, and how to access care in New Jersey — provides a foundation for informed decision-making by individuals and families.

This page covers the neuroscience of heroin addiction, the full spectrum of treatment options, what recovery data actually shows, and the specific resources available in New Jersey.

Understanding Heroin Addiction

How Heroin Affects the Brain

Heroin is a semi-synthetic opioid derived from morphine. When injected, smoked, or snorted, heroin rapidly crosses the blood-brain barrier and is converted back to morphine, which binds to mu-opioid receptors concentrated in brain regions responsible for pain, reward, and autonomic functions.

The neuroscience of heroin addiction involves several interconnected processes:

• Dopamine surge: Heroin triggers a massive release of dopamine in the nucleus accumbens — the brain’s primary reward center — producing the intense euphoria that drives initial use.
• Receptor downregulation: With repeated use, the brain reduces the number and sensitivity of its opioid receptors, requiring more heroin to achieve the same effect (tolerance).
• Endorphin suppression: The brain decreases its own production of endogenous opioids (endorphins, enkephalins), creating a state where normal functioning requires external opioid input (physical dependence).
• Prefrontal cortex changes: Chronic heroin use impairs the prefrontal cortex — the region responsible for judgment, impulse control, and decision-making — making it neurologically harder to choose long-term benefit over immediate relief.

These neurological changes explain why heroin addiction is classified as a chronic brain disorder rather than a behavioral choice. The brain changes are real, measurable, and persistent, though they are also reversible with sustained abstinence and treatment.

The Shift from Prescription Opioids to Heroin

A well-documented pathway exists from prescription opioid misuse to heroin use. According to NIDA, a significant proportion of individuals who develop heroin use disorder first used prescription opioids. The transition typically follows a pattern:

1. Legitimate prescription: An individual receives opioid pain medication for a genuine medical condition
2. Tolerance and dose escalation: Over time, the prescribed dose becomes insufficient, leading to taking more than prescribed
3. Prescription access loss: Prescribing restrictions, insurance limits, or provider awareness cuts off the supply
4. Cost differential: Heroin is significantly cheaper than diverted prescription opioids — a primary driver of the transition
5. Heroin use initiation: The individual begins using heroin, often starting with snorting or smoking before progressing to injection

In New Jersey, this pipeline was amplified by high rates of prescription opioid dispensing during the peak prescribing years. The NJ Prescription Drug Monitoring Program (NJ PDMP), implemented to curb overprescribing, has helped reduce new prescription opioid misuse but did not address individuals who had already transitioned to heroin or illicit fentanyl.

It is important to note that this pipeline, while well-documented, does not represent the experience of all individuals with heroin use disorder. Some individuals begin with heroin directly, and the pathway is more varied than a single narrative suggests.

Treatment Options for Heroin Use Disorder

Medical Detox

Medical detox addresses the acute physical withdrawal from heroin, which typically begins 6 to 12 hours after the last dose and peaks within 36 to 72 hours. Medically supervised detox uses a combination of medications to manage symptoms:

• Buprenorphine (Suboxone/Sublocade): The most effective option for heroin withdrawal, reducing symptoms while also serving as the foundation for ongoing MAT
• Clonidine: Addresses sympathetic nervous system symptoms including elevated heart rate, sweating, and anxiety
• Adjunctive medications: Anti-nausea, anti-diarrheal, sleep, and pain management medications as needed

Detox alone is not treatment for heroin use disorder. NIDA and SAMHSA explicitly state that withdrawal management without subsequent treatment produces outcomes barely better than no treatment at all. The purpose of detox is to stabilize the individual for transition to ongoing care.

Medication-Assisted Treatment

MAT is the evidence-based standard of care for heroin use disorder. Three FDA-approved medications are available:

Buprenorphine (Suboxone/Sublocade): A partial opioid agonist that reduces cravings and blocks euphoria from other opioids.

• Can be prescribed in office-based settings by any physician with a DEA license (the X-waiver requirement was eliminated in 2023)
• Available as sublingual film/tablet (Suboxone), buccal film, or monthly injection (Sublocade)
• Effective at standard doses (8-16 mg/day) for most heroin-dependent individuals
• Long-term retention rates are comparable to methadone in many studies

Methadone (Dolophine/Methadose): A full opioid agonist that eliminates withdrawal and cravings at therapeutic doses.

• Must be dispensed through certified Opioid Treatment Programs (OTPs)
• Requires daily visits initially, with take-home privileges earned over time
• Effective at doses of 60-120 mg/day for most individuals
• Has the longest evidence base of any MAT medication for heroin use disorder

Naltrexone (Vivitrol): An opioid antagonist that blocks all opioid effects.

• Available as a monthly injection, eliminating daily adherence concerns
• Requires complete detox before initiation (typically 7-14 days opioid-free)
• Effective for motivated individuals who have completed detox
• Eliminates the possibility of opioid-induced euphoria while on the medication

Behavioral Therapies

Behavioral therapies complement MAT by addressing the psychological and social dimensions of addiction:

• Cognitive Behavioral Therapy (CBT): Helps individuals identify triggers, develop coping strategies, and modify thought patterns that drive substance use
• Contingency Management: Provides tangible rewards for treatment adherence (negative urine screens, attending appointments), with strong evidence for improving retention
• Motivational Interviewing: A counseling approach that strengthens internal motivation for change
• Community Reinforcement Approach (CRA): Restructures the individual’s environment to make recovery more rewarding than substance use

The combination of MAT and behavioral therapy consistently outperforms either approach alone.

Recovery Rates and Long-Term Outcomes

What the Data Shows

Recovery rate data for heroin use disorder varies significantly depending on how recovery is defined, what treatment was received, and how long individuals are followed:

• Individuals in MAT programs with buprenorphine or methadone show treatment retention rates of approximately 50-60% at one year, with those who remain in treatment showing substantially reduced heroin use, criminal activity, and overdose risk
• NIDA research indicates that treatment lasting at least 90 days produces significantly better outcomes than shorter treatment episodes
• Among individuals who achieve 5 or more years of sustained remission, the probability of maintaining recovery is high, though relapse remains possible at any point
• Recovery trajectories are often non-linear — periods of progress, setback, and renewed commitment are common and expected

Comparing recovery rates across different treatment modalities:

• MAT (buprenorphine or methadone): Highest retention rates, lowest mortality, most consistent outcomes
• Residential treatment with MAT: Strong outcomes, particularly for individuals needing structure
• Abstinence-based residential treatment: Lower retention rates than MAT-inclusive programs, though outcomes improve with treatment duration
• No formal treatment: Lowest probability of sustained recovery, highest mortality risk

Factors That Improve Outcomes

Research has identified several factors consistently associated with better recovery outcomes:

• Treatment duration: Longer engagement in treatment predicts better long-term results
• MAT adherence: Continued use of buprenorphine, methadone, or naltrexone (Vivitrol) as prescribed
• Stable housing: Homelessness is a significant predictor of poor outcomes
• Employment: Vocational engagement provides structure, purpose, and financial stability
• Social support: Strong recovery networks, including peer support and family involvement
• Mental health treatment: Addressing co-occurring depression, anxiety, PTSD, and other conditions
• Absence of ongoing substance-using social networks: Reducing exposure to substance-use cues and peers

Recovery Without Formal Treatment

Natural Recovery Research

The search query “recovery from heroin without treatment” reflects a genuine question that deserves an honest answer. Research does document that some individuals recover from substance use disorders, including heroin use disorder, without formal treatment. This phenomenon — sometimes called “natural recovery” or “spontaneous remission” — has been studied in population surveys.

Factors associated with natural recovery include:

• Maturation effects (aging out of substance use)
• Major life changes (new relationships, parenthood, employment)
• Health scares or overdose experiences
• Relocation away from substance-using environments
• Spiritual or personal development

Why Treatment Still Matters

While natural recovery exists, several realities argue strongly for formal treatment, particularly for heroin and fentanyl use disorder:

• Mortality risk during active use: Every day of ongoing heroin/fentanyl use carries overdose risk. The current fentanyl-contaminated drug supply has made this risk dramatically higher than in previous decades.
• Time to recovery: Natural recovery, when it occurs, typically happens after many years of active use. Formal treatment accelerates the process.
• Quality of recovery: Individuals who receive treatment — particularly MAT — tend to achieve more stable, comprehensive recovery with fewer relapse episodes.
• Medical risk reduction: MAT reduces not only overdose risk but also the risk of HIV, hepatitis C, endocarditis, and other medical complications of heroin use.

For individuals who are not ready for formal treatment, harm reduction strategies — including naloxone (Narcan) access, fentanyl test strips, and syringe services — can reduce the risks of continued use while the individual moves toward readiness for treatment.

Heroin Addiction Treatment in New Jersey

NJ Treatment Landscape

New Jersey has a comprehensive addiction treatment infrastructure that includes:

• Licensed treatment programs: Hundreds of DMHAS-licensed facilities across the state offering detox, residential, outpatient, and MAT services
• Opioid Treatment Programs (OTPs): Multiple methadone clinics across NJ counties
• Office-based buprenorphine treatment: Expanding network of physicians prescribing buprenorphine in primary care and specialty settings
• State-funded programs: NJ provides treatment funding for individuals without insurance through the state’s substance abuse initiative
• NJ Medicaid coverage: Covers all FDA-approved MAT medications, behavioral therapy, and recovery support services

Accessing Care

For individuals seeking heroin addiction treatment in New Jersey:

• NJ Substance Abuse Treatment Hotline (1-844-276-2777): Free, confidential referrals to treatment programs statewide
• NJ CARES: Connects individuals to treatment within 24 hours, including emergency department warm handoffs
• SAMHSA Treatment Locator (findtreatment.gov): National database of treatment programs searchable by location, service type, and payment
• NJ 211: Provides referrals to treatment, transportation, housing, and other support services
• Naloxone (Narcan) access: Available without a prescription at all NJ pharmacies and free through community organizations

---

This article is part of our complete guide to opioid addiction in New Jersey. For information about fentanyl specifically, see fentanyl addiction: signs, dangers, and treatment. For details on Suboxone treatment, visit Suboxone treatment: how it works.

For information on medication-assisted treatment, see our guide to MAT. For recovery outcome data, visit recovery rates and long-term outcomes.